December 23, 2025 · Form 4 insider transaction
PASQUALONE FRANK bought 7,633 shares of Enveric Biosciences, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 7 days after the transaction.
Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.; On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "January Reverse Stock Split"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the"October Reverse Stock Split" together with the January Reverse Stock Split, the "Reverse Stock Splits"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.